CNBC July 2, 2024
Key Points
– The Food and Drug Administration approved Eli Lilly’s Alzheimer’s drug donanemab, expanding the limited treatment options for the mind-wasting disease.
– It’s a long-awaited win for Eli Lilly after donanemab faced several delays in its path to market.
– Donanemab and a similar treatment called Leqembi from Biogen and Eisai are milestones in the treatment of Alzheimer’s after three decades of failed efforts to develop medicines that can fight the fatal disease.
The Food and Drug Administration on Tuesday approved Eli Lilly‘s Alzheimer’s drug donanemab, expanding the limited treatment options for the mind-wasting disease in the U.S.
The agency approved the treatment, which will be sold under the brand name Kisunla, for adults with early...
Today's Sponsors
Today's Sponsor